MIRAE ASSET
HEALTHCARE FUND - (MAHCF)
(Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors)
| Type of Scheme | Sectoral/Thematic Fund - An open ended equity scheme investing in healthcare and allied sectors |
| Investment Objective | The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns. |
Fund Manager** |
Mr. Vrijesh Kasera (since July 02, 2018) |
| Allotment Date | 02nd July, 2018 |
| Benchmark Index | S&P BSE Healthcare Index (TRI) |
| Minimum Investment Amount |
₹ 5,000/- and in multiples of ₹ 1/-thereafter. Minimum Additional Application Amount: ₹ 1,000/- per application and in multiples of ₹ 1/- thereafter. |
Systematic Investment Plan (SIP) (Any Date SIP is available from 1st July, 2019) |
Monthly and Quarterly: ₹ 1,000/- (multiples of ₹ 1/- thereafter), minimum 5 in case of Monthly or 3 in case of Quarterly option. |
| Load Structure | Entry load: NA Exit load: I. For investors who have opted for SWP under the plan: a) 15% of the units allotted (including Switch-in/STP - in) on or before completion of 365 days from the date of allotment of units: Nil. b) Any redemption in excess of such limits in the first 365 days from the date of allotment shall be subject to the following exit load: (Redemption of units would be done on First In First Out Basis (FIFO): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL II. Other Redemptions: For Investors who have not opted for SWP under the plan (including Switch out, STP out): •If redeemed within 1 year (365 days) from the date of allotment: 1% •If redeemed after 1 year (365 days) from the date of allotment: NIL |
| Plans Available | Regular Plan and Direct Plan |
| Options Available | Growth Option and IDCW^ Option (Payout & Re-investment) |
| Monthly Average AUM (₹ Cr.) as on Febraury 28, 2022 |
1,796.51 |
| Net AUM (₹ Cr.) | 1,736.03 |
| Monthly Avg. Expense Ratio (Including Statutory Levies) as on Febraury 28, 2022 |
Regular Plan: 2.09% Direct Plan: 0.57% |
| **For experience of Fund Managers Click Here | |
| ^Pursuant to Notice cum addendum dated March 27, 2021 the nomenclature of dividend option has been changed w.e.f. April 01, 2021. | |
| NAV: | Direct | Regular |
| Growth | ₹ 22.712 | ₹ 21.420 |
| IDCW | ₹ 22.704 | ₹ 21.417 |
| Volatility | 21.10% |
| Beta: | 0.91 |
| R Squared | 0.97 |
| Sharpe Ratio#: | 1.17 |
| Information Ratio | 2.15 |
| Portfolio Turnover Ratio | 0.26 times |
@The Volatility, Beta, R Squared, Sharpe Ratio & Information Ratio are calculated on returns from last three years Monthly data points. # Risk free rate: FBIL OVERNIGHT MIBOR as on 28th February, 2022.^Basis last rolling 12 months. |
|
| New Position Bought |
| Stock |
| Pharmaceuticals |
| Laurus Labs Limited |
| Positions Increased |
| Stock |
| Insurance |
| ICICI Lombard General Insurance Company Limited |
| Max Financial Services Limited |
| Healthcare Services |
| Fortis Healthcare Limited |
| Pharmaceuticals |
| Aurobindo Pharma Limited |
| Lupin Limited |
| IPCA Laboratories Limited |
| Torrent Pharmaceuticals Limited |
| Gland Pharma Limited |
| Ajanta Pharma Limited |
| Alkem Laboratories Limited |
| Positions Decreased |
| Stock |
| Healthcare Services |
| Vijaya Diagnostic Centre Limited |
| Apollo Hospitals Enterprise Limited |
| Pharmaceuticals |
| Divi's Laboratories Limited |
| Biocon Limited |
| Portfolio Holdings | % Allocation | |
| Pharmaceuticals | ||
| Sun Pharmaceutical Industries Ltd | 15.14% | |
| Dr. Reddy's Laboratories Ltd | 8.97% | |
| Cipla Limited | 7.79% | |
| Torrent Pharmaceuticals Ltd | 5.56% | |
| IPCA Laboratories Limited | 5.04% | |
| Divi's Laboratories Ltd | 4.24% | |
| Gland Pharma Limited | 3.53% | |
| JB Chemicals & Pharmaceuticals Limited | 3.24% | |
| Lupin Limited | 3.19% | |
| Aurobindo Pharma Ltd | 3.15% | |
| Natco Pharma Limited | 2.99% | |
| Ajanta Pharma Ltd | 2.96% | |
| Biocon Ltd | 2.35% | |
| Alkem Laboratories Limited | 2.01% | |
| Laurus Labs Limited | 1.09% | |
| Abbott India Limited | 0.00% | |
| Sanofi India Limited | 0.00% | |
| Healthcare Services | ||
| Apollo Hospitals Enterprise Limited | 8.58% | |
| Fortis Healthcare Limited | 3.98% | |
| Krishna Institute Of Medical Sciences Limited | 3.29% | |
| Tarsons Products Limited | 1.32% | |
| Dr. Lal Path Labs Limited | 1.26% | |
| Vijaya Diagnostic Centre Limited | 0.53% | |
| Syngene International Limited | 0.49% | |
| Insurance | ||
| ICICI Lombard General Insurance Company Limited | 1.73% | |
| Max Financial Services Ltd | 1.44% | |
| SBI Life Insurance Company Limited | 1.34% | |
| Chemicals | ||
| Vinati Organics Ltd | 2.08% | |
| Tatva Chintan Pharma Chem Limited | 1.58% | |
| Equity Holding Total | 98.89% | |
| Cash & Other Receivables | 1.11% | |
| Total | 100.00% | |
| Returns (in%) | ||||
| 1 Yr | 3 Yrs | SI | ||
| MAHCF | 17.62% |
28.00% |
23.12% |
|
| Scheme Benchmark* | 12.54% |
20.13% |
15.94% |
|
| Additional Benchmark** | 15.65% |
17.49% |
14.87% |
|
| NAV as on 28th February, 2022 | 21.420 | |||
| Index Value (28th February, 2022) | Index Value of Scheme benchmark is 26,467.37 and S&P BSE Sensex (TRI) is 84,075.57 | |||
| Allotment Date | 02nd July, 2018 | |||
| Scheme Benchmark | *S&P BSE Healthcare Index (TRI) | |||
| Additional Benchmark | **S&P BSE Sensex (TRI) | |||
Fund manager : Mr. Vrijesh Kasera managing the scheme since July 02, 2018
Note: Returns below or for 1 year are absolute returns, returns above 1 year are CAGR- Compounded Annualized Growth returns.
| Period | Total Amount Invested | Mkt Value as on 28-February-2022 |
SI |
430,000 |
678,353 |
3 Yr |
360,000 |
535,112 |
1 Yr |
120,000 |
116,972 |
Returns (%) |
Period |
||
SI |
3yr |
1yr |
|
Fund Return& (%) |
26.31 |
27.60 |
-4.69 |
Benchmark Return& (%) |
19.73 |
21.51 |
-8.80 |
Add. Benchmark Return& (%) |
18.66 |
20.54 |
7.40 |
& The SIP returns are calculated by XIRR approach assuming investment of ₹ 10,000/- on the 1st working day of every month.
This product is suitable for investors who are seeking*
• To generate long term capital appreciation
• Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India
*Investors should consult their financial advisers if they are not clear about the suitability of the product.
Past Performance may or may not be sustained in future.
Note : For computation of since inception returns (%) the allotment NAV has been taken as ₹ 10.00. The performance of other funds managed by the same fund manager is given in the respective page of the schemes 
Different Plans under the scheme has different expense structure. The reference and details provided here in are of Regular Plan - Growth Option